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Abstract: 
 
BACKGROUND/AIMS : To evaluate the vitreous signals obtained on spectral 
domain optical coherence tomography (SD-OCT) in patients with uveitic cystoid 
macular oedema (CMO) and compare these signals before and after sub-Tenon’s 
triamcinolone acetonide injection.  
METHODS 
Design: Retrospective study with standardised longitudinal imaging pre- and post-
intervention.  The study cohort comprises 22 patients (22 eyes) with uveitic CMO 
receiving a Sub-Tenon’s Triamcinolone Acetonide (STTA) injection. Post-hoc 
analysis of SD-OCT images using custom software provided an “absolute” 
measurement of vitreous signal intensity, which was expressed as a ratio to the 
retinal pigment epithelium intensity (“VIT/RPE-relative intensity”) in arbitrary units.  
Main Outcome Measure: Difference in VIT/RPE-relative intensity before and after 
treatment.  
RESULTS:  Treatment with STTA resulted in a significant reduction in VIT/RPE-
Relative Intensity, which was associated with both a reduction in central retinal 
thickness (CRT) and improvement in visual acuity. Mean (SD) VIT/RPE-Relative 
Intensity pre-treatment was 0.139 (0.074) vs. 0.053 (0.028) post-treatment (p=3x10-
5). Mean (SD) CRT was 581μm (119μm) pre-treatment vs 333μm (95μm) post-
treatment (p=2x10-8); the mean reduction in CRT was 248 (95%CI: 189-306). The 
correlation coefficient between VIT/RPE-Relative Intensity and CRT was 0.534 
(p=0.011) and between VIT/RPE-Relative Intensity and visual acuity was 0.702 
(p=0.0001). 
CONCLUSION: This study provides evidence that the OCT-derived VIT/RPE-
Relative intensity may be useful as a quantitative and objective marker of disease 
activity and treatment response in uveitis complicated by CMO. This first longitudinal 
study of this novel OCT parameter is an encouraging step in the development of 
sensitive objective OCT-based endpoints for trials of efficacy in uveitis. 
 
  
Introduction 
 
Uveitis, a group of conditions characterised by intraocular inflammation, is a 
major cause of blindness worldwide (1). The commonest cause of sight loss in uveitis 
is cystoid macular oedema (CMO), which accounts for around a third of blindness 
caused by the disease (2). CMO may be reversible with prompt corticosteroid 
treatment (3) such as with Sub-Tenon’s triamcinolone acetonide (STTA), leading to 
visual recovery (4-6).   
Vitreous inflammation can be seen on examination as a characteristic “haze”, 
caused by the presence of proteinaceous exudate in the vitreous. The level of 
vitreous haze is considered to be a good marker of inflammation in the underlying 
uveal tract. For this reason the National Eye Institute (NEI) “Vitreous Haze Score” is 
the trial endpoint most commonly accepted by regulatory bodies. The NEI scale is 
determined by examining the vitreous using an indirect ophthalmoscope with 
comparison to standardised photographs. Weaknesses are that it is subjective, non-
continuous, poorly discriminatory at lower levels of inflammation and has low 
sensitivity in a clinical trial context (7-10).  
 Optical coherence tomography (OCT), an imaging modality that provides high 
resolution, cross sectional images of ocular tissues non-invasively is well-established 
in the measurement of macular pathology, including macular oedema (11-13). Most 
analysis of OCT images is qualitative, but quantitative analysis  - such as the 
measurement of central macular thickness in macular oedema – provides an 
objective and sensitive measure of deviation from normal, change over time and 
response to therapy. We and others are using these principles to develop measures 
all the key components of intraocular inflammation, such that the clinical assessment 
of uveitis may become more objective and reliable (8, 14-18). We have shown in two 
independent cohorts using two different OCT-platforms that measurements of 
vitreous inflammation derived from OCT scans are repeatable, reliable and 
correlated with clinical measures of disease activity, notably  the NEI Vitreous Haze 
Score (17-18). To help ensure internal standardisation, we utilised the reflective 
intensity of the retinal pigment epithelium (RPE) as a reference, thereby producing a 
ratio (“VIT/RPE-Relative Intensity) (17-18)..  
 The aim of this paper is to further validate the use of the VIT/RPE-Relative 
Intensity as a marker of disease activity in uveitis by assessing whether it is capable 
of detecting changes in the vitreous pre-/post-STTA, and whether these correlate 
with other signs of reduction in disease activity.  
 
  
Materials and Methods 
 
Study Population: 
 This is a retrospective, longitudinal study comprising 22 patients with uveitic CMO 
attending a tertiary uveitis clinic at the Birmingham & Midlands Eye Centre, Sandwell 
& West Birmingham Hospitals NHS Trust, United Kingdom. All patients had a 
complete ophthalmic assessment including visual acuity, slit lamp examination, 
grading of anterior chamber inflammation, intraocular pressure measurement, fundus 
examination and grading of vitreous inflammation using the NEI Vitreous Haze 
Score. Approval for data collection and analysis was obtained from a U.K. National 
Health Service research ethics committee and adhered to the tenets set forth in the 
Declaration of Helsinki. All patients were consented for posterior STTA 
administration.  
 
Procedure: 
Povidone iodine and oxybuprocaine drops were used to sterilize and anesthetize the 
eye before the procedure. The conjunctiva and sub-Tenons layer were lifted 10mm 
from the limbus superotemporally using blunt serrated forceps. The sub-Tenon’s 
cannula was attached to a 2ml syringe containing 1ml of 40mg/ml triamcinolone 
acetonide, and inserted, advancing the needle 12-14mm into the posterior sub-
Tenons space into which the full dose (i.e. 40mg triamcinolone acetonide) was 
administered (19).  
 
Image Acquisition: 
Optical coherence tomographic image sets were obtained using Heidelberg 
Spectralis OCT (Heidelberg Engineering, Germany). The images were obtained 
immediately prior to the procedure and at the first subsequent clinical review. The 
volume scan images were centred on the fovea and the TruTrack Active and 
AutoRescan features were used to ensure that follow-up scans were matched to the 
baseline scan.. The enhanced depth protocol was not used.  
 
Quantitative Assessment of Vitreous Signal Intensity: 
As per our previously published protocol, OCT scan images were imported into 
‘OCTOR’, a program for easy navigation and manual grading of the scans validated 
in previous studies (20-21). Masked to all clinical data, primary graders marked out 1) 
the uppermost extent of the vitreous space included in the scan - the “vitreous top”, 
2) the internal limiting (ILM) membrane, 3) the inner layer of the RPE, and 4) the 
outer layer of the RPE on all the scans. This was done on five sections going 
through the central fovea subfield of the Early Treatment Diabetic Retinopathy Study 
(ETDRS) grid. The area between lines 1 and 2 was defined as the “vitreous 
space”(VIT), whilst the area between 3 and 4 was defined as the “RPE space” 
(RPE). The software then calculated the mean intensity values of all image pixels 
contained within each space as absolute values. A relative value, the VIT/RPE-
Relative Intensity, could then be derived to minimise the potential effects of 
confounders such as lens opacities or anterior chamber inflammation (Figure 1).  
 
Statistical Analyses: 
Clinical and imaging data were analyzed with frequency and descriptive statistics. 
Snellen visual acuities were converted to LogMAR (logarithm of the minimum angle 
of resolution) visual acuity for the purposes of statistical analysis. Spearman’s 
correlation was used to assess the relationship between the VIT/RPE-Relative 
Intensity and clinical/retinal imaging parameter.  The Mann-Whitney U test was used 
in independent samples and Wilcoxon Signed Ranks test in dependent samples. 
Statistical analysis was performed using IBM SPSS software version 20.0 for 
Windows (SPSS, Inc, Chicago, Illinois, USA). P values < 0.05  were considered 
significant. 
 
  
Results 
 
Baseline Characteristics: 
The study included 22 eyes of 22 patients, before and after treatment with STTA. 
Their baseline characteristics are listed in Table 1. 
 
VIT/RPE-Relative Intensity 
Treatment with STTA was associated with a significant reduction in OCT-measured 
VIT/RPE-Relative Intensity (Figure 2). The mean (SD) VIT/RPE-Relative Intensity 
pre-treatment was 0.139 (0.074) vs. 0.053 (0.028) post-treatment (p=3x10-5).  
 
Mean Central Retinal Thickness 
Treatment with STTA was associated with significant reduction in the OCT-
measured mean central 1 mm of retinal thickness (CRT). Mean (SD) CRT was 
580.5μm (119.4μm) pre-treatment vs 332.7μm (95.4μm) post-treatment (p=2x10-8); 
the mean reduction in CRT was 247.7 (95%CI: 189.1-306.3). The correlation 
coefficient between VIT/RPE-Relative Intensity and CRT was 0.534 (p=0.011; Figure 
3). 
 
 
Visual acuities 
Treatment with STTA was associated with significant improvement in visual acuity 
(p=0.0001). The number of patients with a visual acuity greater than 6/12 increased 
from 1 (4.54%) to 17 (77.3%) with a corresponding reduction in those with 6/12 or 
worse from 19 (86.4%) to 5 (22.7%) (Fisher exact test, p=0.0001). The correlation 
coefficient between VIT/RPE-Relative Intensity and visual acuity was 0.702 
(p=0.0001; Figure 4).  
 
Discussion 
This study provides the first ‘treatment-response’ data to support our proposal 
that OCT can be used to provide an objective measure of treatment response in 
uveitis based on changes in the vitreous. It builds on our previous feasibility study in 
which we demonstrated proof of concept that the VIT/RPE-Relative Intensity could 
provide an objective and quantitative measure of vitreous inflammation. Both that 
cross-sectional study and a validation study in an independent cohort showed that 
the VIT/RPE-Relative Intensity was higher in uveitic eyes with active inflammation 
than uveitic eyes without active inflammation or healthy controls, and that it 
correlated with the clinical NEI vitreous haze score (17-18).We also showed 
association with other markers of disease activity such as visual acuity, AC cells and 
AC flare. Importantly the VIT/RPE Relative Intensity was also shown to be a 
repeatable measure with high inter-grader reproducibility (17-18). 
 
 In this study we have demonstrated that the VIT/RPE-Relative Intensity 
decreases significantly in response to STTA and that this reduction was associated 
with improvement in another measurable sign of disease activity, CMO.  Critically 
this study demonstrates VIT/RPE-Relative intensity is sensitive enough to measure 
changes in the vitreous undetectable using the clinical NEI Vitreous Haze Score.  As 
highlighted by a number of authors, the poor discrimination of the NEI Vitreous Haze 
Score at lower levels has led most clinical trials in this field to require subjects to 
have a minimum NEI Vitreous Haze Score of 2+ for inclusion. This has significantly 
limited enrolment (7-10,22). In an observational study comparing a photographic-
based score to the NEI score, Hornbeak noted that had they used the traditional ‘cut-
off’ 86% of participants would have been excluded. Although a significant proportion 
of that cohort were scored as 0 on the NEI Vitreous Haze Score it cannot be argued 
that all these cases were inactive as both the Hornbeak study and our current study 
indicate that an appropriately sensitive tool is able to discriminate within this group 
(9). Whereas the Hornbeak study was cross-sectional, our longitudinal study is the 
first to show a tool capable of detecting change in uveitis activity within these lower 
levels of inflammation, even when both the pre-treatment and post-treatment clinical 
Vitreous Haze Score was 0.  
 
There is an urgent need to develop sensitive objective measures of 
inflammation in uveitis, for use as endpoints in clinical trials and to inform treatment 
decisions in routine clinical practice. The FDA advises that a trial endpoint must be 
‘well-defined and reliable’ and recommends that treatment benefit should be a 
measure of how a patient “survives, feels or functions”. Other measures that do not 
capture these are regarded as “surrogate measures of benefit”. 
 
All measures of disease activity in uveitis are “surrogate measures”. The FDA 
requires a surrogate to be “reasonably likely, based on epidemiologic, therapeutic, 
pathophysiologic, or other evidence to predict clinical benefit”., In the context of 
developing and assessing surrogate measures for use as trial endpoints in uveitis, 
we propose that they must meet two essential criteria: (1) The surrogate should be 
‘biologically relevant’ given our understanding of the pathophysiology of the disease; 
and (2) The surrogate should be ‘functionally relevant’ with evidence of a 
downstream effect on visual function, but recognizing that this effect may be delayed 
and indirect. Provided a surrogate satisfies these criteria, it should then be assessed 
for  desirable criteria such as objectivity, repeatability, and sensitivity, 
 
This study provides further evidence of the biological and functional relevance 
of VIT/RPE relative intensity..Its biological relevance is demonstrated by its 
association with other markers of inflammation such as the central retinal thickness. 
Its functional relevance is supported by its correlation with visual recovery, however 
it is recognized that this is largely indirect, the primary mechanism of improvement 
being the restoration of central macular architecture as the oedema resolves.  
 
The OCT-derived VIT/RPE-Relative intensity is the first instrument-measured 
marker of vitreous inflammation, and is an example of how extended applications of 
OCT and other imaging modalities have the potential to revolutionise our approach 
to the diagnosis, assessment and management of uveitis. Research into VIT/RPE-
Relative intensity levels during the development of CME and its relation to vascular 
changes visualized on fluorescein angiography may inform our understanding of the 
natural history of this sight-threatening complication, and help guide treatment.. 
 
Furthermore the sensitivity of this small study to detect a change at a highly 
statistically significant level (p = 0.00003), shows how the acceptance of OCT-
derived objective indices could transform our approach to effectiveness trials in 
uveitis.  .The limitations of our current endpoints in uveitis provide major constraints 
to effectiveness trials (7-10,23), which may lead to a trial ‘failing’ (i.e. not meeting its 
primary endpoint) even in the presence of an effective therapy. This in turn 
discourages further investment, and leads to an absence of high-quality trial data to 
inform clinicians, funders and policy makers with regard to main of therapies being 
considered for use in uveitis. The high sensitivity and reproducibility of instrument-
based measures such as the OCT-derived VIT/RPE relative intensity can provide 
endpoints with much higher ’signal:noise’ ratio than current clinical measures 
enabling smaller, faster, cheaper trials. Such endpoints can already be adopted as 
‘signals’ to inform investment decisions in early phase studies, but their adoption in 
later-phase licensing studies will depend on achieving the further validation required 
by regulatory bodies such as the FDA.  
 
Study limitations  
This study involves retrospective analysis of longitudinal OCT image sets 
obtained from a small number of patients with uveitis and OCT-confirmed CMO. It 
therefore has the limitations of a retrospective design, and we acknowledge that 
given the nature of this cohort the focus of the clinical assessments at the time will 
have been directed towards the CMO, and not on accurate grading of the clinical 
vitreous haze. We also note that visual acuity data were recorded as Snellen 
measurements rather than the preferred LogMAR notation. It should be noted 
however that the primary focus of this paper is on the post-hoc analysis of the OCT 
image sets and their change over time, rather than on the associated clinical 
changes. 
 
The design of the study was pragmatic in using scans conducted under 
normal macular scanning conditions. We and others have proposed a number of 
techniques for optimising the visualisation of vitreous using current Spectral Domain 
and emerging technology (8,10, 17-18). Increasing the proportion of the vitreous 
which is visualised is likely to improve this technique further, enhancing sensitivity 
and repeatability; it also enables anatomic localisation of foci of inflammation within 
the vitreous cavity related to the distribution and type of uveitis.  
 
This study is based on a small cohort, with a range of uveitic diagnoses. This 
heterogeneity is common in uveitis studies (8,10), and indeed the consistent 
performance of the VIT/RPE relative intensity tool across this range of patients is 
very encouraging for its future usefulness is an outcome measure. Critically, despite 
its size and heterogeneity, the study achieved its primary endpoint at a high level of 
statistical significance . 
 
A barrier to the potential adoption of our technique as described in this study 
is that it is time-consuming, taking around 3-5 minutes per scan. Recently however 
we have developed a software package for automation of this process. This custom 
software entitled VITreous ANalysis (VITAN) can segment and annotate the scans 
automatically, reducing the time taken to derive measures of vitreous reflectivity to a 
few seconds per scan, with benefits in speed, cost, and further reduction of 
subjectivity or human error in marking the boundaries of anatomical structures (24).  
 
 To conclude, in this study we have further demonstrated the relevance of the 
OCT-derived VIT/RPE-Relative intensity as a quantitative and objective marker of 
disease activity and treatment response in uveitis complicated by CME. This first 
longitudinal study of this novel OCT parameter is an encouraging step in the 
development of sensitive objective OCT-based endpoints for trials of efficacy in 
uveitis.   
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Tables and figures: 
TABLE 1: Baseline Characteristics 
Age  47.4 years ( 23y – 74y) 
Gender 
 
Female 
Male 
 
 
17 (77%) 
5 (23%) 
Anatomical Site of Uveitis 
 
Panuveitis 
Intermediate Uveitis 
Anterior Uveitis 
 
 
10 (45%) 
8 (36%) 
4 (18%) 
Aetiology 
 
Idiopathic 
Sarcoidosis 
TINU 
Behcet’s 
Reiter 
VKH 
 
 
14 (64%) 
4 (18%)  
1 (5%) 
1 (5%) 
1 (5%) 
1 (5%) 
AC Cells 
 
 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
6 
6 
4 
4 
0 
0 
2 
AC Flare 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
 
 
12 (54.54%) 
2 (9.09%) 
6 (27.27%) 
0 
0 
0 
2 (9.09%) 
Vitreous haze 
 
0 
0.5+ 
1+ 
2+ 
3+ 
4+ 
Not available 
 
 
15 (68.18%) 
0 
2 (9.09%) 
1 (4.54%) 
0 
0 
4 (18.18%) 
  
Timing of Post-Intervention Review 
Median (range) duration to follow-up 
OCT scan and review post-treatment 
 
7 weeks (4 – 19 weeks) 
  
 
Figure 1. Quantitative assessment of the vitreous using OCT 
demonstrated in a 47 year old male with intermediate uveitis (A,B) and a 
48 year old female with panuveitis (C,D). Both patients were assessed 
by standard macular-focussed OCT both before (A,C) and after (B,D) 
treatment with Sub-Tenon’s Triamcinolone Acetonide (STTA), with 
calculation of the Vitreous/RPE-Relative Intensity (Vit/RPE RI).. 
  
Figure 2. VIT/RPE–Relative Intensity before and after treatment with 
Sub-Tenon Triamcinolone Acetonide (STTA) for Uveitic Cystoid Macular 
Oedema (CMO). 
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Figure 3. Correlation between change in VIT/RPE–Relative intensity and 
change in mean central retinal thickness.
  
 
Figure 4. Correlation between change in VIT/RPE–Relative intensity and 
change in visual acuity. 
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